OTCM
PPTMF
Market cap576kUSD
, Last price
USD
Name
Pharmacolog I Uppsala AB (publ)
Chart & performance
P/E
—
P/S
—
EPS
0.54
Vol. 1Y
—
Shs. 5Y
-19.89%
Rev. 5Y
50.26%
Div Yld LY
—
Div Yld TTM
—
Revenues
15m
+109.83%
Net income
2m
P
CFO
-5m
L-22.26%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 2007 and based in Uppsala, Sweden, Pharmacolog i Uppsala AB (publ) creates innovative systems and solutions to improve the safety and precision of intravenous drug handling. Their offerings include DrugLog, a system engineered to minimize errors during medication administration. They also provide WasteLog, a specialized device for analyzing and managing discarded or returned injectable controlled substances. Additionally, PrepLog, an advanced platform leveraging DrugLog technology, seamlessly connects with prescription and medication management software to verify drug preparations.
Key people
Erik Hedlund
Independent Chairman of the Board · since 2017
Karl-Erik Carlstrom
Chief Executive Officer · since 2016
Susanne Grimsby
Manager QA-RA
Lars Gusch
Development Manager · since 2019
Torbjorn Norberg
Product Manager · since 2018
Director · since 2019
Independent Director · since 2019
Jorgen Jonsson
Chief Financial Officer
Headquarters & legal address
C/O Oncodia AB
Knivstagatan 8
Uppsala, C 753 23
SE
Knivstagatan 8
Uppsala, C 753 23
SE
Previous name
Pharmacolog i Uppsala AB
Previous name
Pharmacolog i Uppsala AB (publ)
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||